Moderna Inc. faces a notable decline in stock value amidst broader market movements.
Moderna Inc. (NASDAQ:MRNA) is experiencing a downturn, with shares sliding by 2.28% to close at CA$184.63. This decline comes as part of a broader market response to mixed economic signals and investor sentiment.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$75.43B
52W high
$208.90
52W low
$22.28
1W change
-3.02%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Oct 2, 2026
Wall Street analysts forecast MRNA stock price to fall 36.1% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$120.67
-36.1% Upside
Previously C$119.56 on Sep 17, 2026
Current Price
C$188.94
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
116.3%
Annualized
90-Day Vol
210.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$225.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$200.53 | C$134.24 – C$299.55 |
| 60 trading days | C$212.83 | C$120.65 – C$375.41 |
| 90 trading days | C$225.88 | C$112.72 – C$452.64 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Moderna's recent performance may reflect underlying challenges in the biotech sector, despite its upcoming inclusion in the Nasdaq-100 Index.
Moderna's stock falls 2.28%
Despite a promising premarket rise, Moderna's stock faced significant selling pressure during regular trading hours.
Bull case
The expected inclusion in the Nasdaq-100 Index could create demand for Moderna shares, potentially stabilizing or boosting the stock over time.
Bear case
The current decline highlights vulnerabilities in Moderna's business model and profitability, especially considering its negative profit margin and lack of dividend yield.
Advertisement
Market Context
Today's market saw mixed signals, with U.S. stock index futures rising, yet Moderna's stock could not capitalize on this momentum. The broader economic outlook remains uncertain, impacting investor confidence in biotech stocks.
Challenges Ahead
Moderna's negative profit margin and lack of dividend yield are concerning for investors. The company's recent stock performance raises questions about its ability to maintain growth and profitability in a competitive market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
